Leukaemia is a common cancer of the haematopoietic system. The main forms, such as chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML), sometimes differ considerably in terms of diagnostic and therapeutic options. Keep reading for modern approaches such as molecular diagnostics and targeted therapies.
Using data from more than 400,000 individuals, researchers have created a platform for predicting the risk of developing blood cancers such as acute myeloid leukaemia over a 10-15-year period.
AI could find critical biomarkers that predict non-response to conventional treatment in patients with chronic myeloid leukaemia (CML) more quickly, researchers in Singapore find.
A collaborative study has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukaemia (CLL), and associated these with clinical outcomes.
Some leukemias evade treatment by changing their appearance and identity through changing the read-out of their DNA, a new study has found.
The oncogene EVI1 causes an aggressive type of leukemia, but its exact function has been a mystery. A research team now showed that EVI1's cancer causing effect relies on activating a single gene — the stem cell transcription factor ERG.
A blood test could predict risk of developing leukaemia in the elderly population years in advance by identifying changes in blood cell production, according to new research.
Scientists from Hokkaido University have identified new targets for treating Adult T-cell leukemia/lymphoma (ATLL), an aggressive form of blood cancer with existing drugs.
New research from the University of East Anglia (UEA) and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.
By analysing secondary acute myeloid leukaemias, researchers at the Institute for Research in Biomedicine (IRB) Barcelona have detected mutations caused by platinum-based chemotherapies in cells that were healthy at the time of treatment. Treatment with chemotherapies influences the development of blood cells, favouring clonal hematopoiesis from cells with pre-existing mutations. The study has…
Communities benefit from sharing knowledge and experience among their members. Following a similar principle - called “swarm learning” - an international research team has trained artificial intelligence algorithms to detect blood cancer, lung diseases and Covid-19 in data stored in a decentralized fashion. This approach has advantage over conventional methods since it inherently provides…
New research has uncovered a surprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases. In the new study from Children’s Medical Center Research Institute at UT Southwestern (CRI), scientists made the unexpected discovery that these DNA sequences, also known as transposons, can protect against certain blood cancers. These…
B-cell lymphocytosis, a condition in which individuals have increased levels of particular white blood cells, in some cases leads to blood cancer. As an international team of researchers now shows in samples from patients, both diseases exhibit similar epigenetic signatures that are forming very early during the course of the disease. Chronic leukemias often start insidiously. White blood cells…
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research. “The results provide more justification and rationale for starting the clinical trial in May,” said first author John Mackey, professor and director of oncology clinical…
Leukemia frequently originates from the so-called leukemic stem cell, which resides in a tumor promoting and protecting niche within the bone marrow. Scientists from the Max Planck Institute of Biochemistry in Martinsried, Germany, have found a new way to make these cells vulnerable by specifically dislodging these cells from their niches.
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19. Researchers observed that the off-label use of the cancer drug acalabrutinib, a BTK inhibitor that is approved to treat several blood cancers, was associated with reduced respiratory distress and a reduction in the overactive…
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma, a blood cancer, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, in December. This is the first study to experimentally determine which…
For the first time, researchers from Helmholtz Zentrum München and the University Hospital of LMU Munich show that deep learning algorithms perform similar to human experts when classifying blood samples from patients suffering from acute myeloid leukemia (AML). Their proof of concept study paves the way for an automated, standardized and on-hand sample analysis in the near future. The paper was…
Researchers at the University of Birmingham have shown that it’s possible to produce a compound with anti-cancer properties directly from feverfew – a common flowering garden plant. The team was able to extract the compound from the flowers and modify it so it could be used to kill chronic lymphocytic leukaemia (CLL) cells in the laboratory. Feverfew is grown in many UK gardens, and also…
Oxford Gene Technology (OGT), A Sysmex Group Company, has celebrated the opening of its new facility in Cambridge, UK. The opening ceremony, which took place at the company’s new premises on the prestigious Cambridge Science Park, was attended by the Department for International Trade (DIT) and local media as well as top-level representatives from OGT and its parent company, Sysmex Corporation.…
